Fibroblast Growth Factor 23: Mineral Metabolism and beyond

Alexander Grabner, Sandro Mazzaferro, Giuseppe Cianciolo, Stefanie Krick, Irene Capelli, Silverio Rotondi, Claudio Ronco, Gaetano La Manna, Christian H Faul

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients affected by chronic kidney disease (CKD) exhibit a high risk of cardiovascular mortality that is poorly explained by traditional risk factors. There is a growing awareness about the role of derangement of mineral metabolism that is currently accepted as a trigger and sustainer of cardiovascular disease (CVD) in CKD patients. The synthetic definition of CKD mineral and bone disorder (CKD-MBD) split the concept that the indexes of mineral metabolism extend their effects beyond the bone until the vascular wall and metabolic milieu of CKD patients through complex pathways. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy, CVD, inflammation, and chronic renal damage may help with the diagnosis and treatment of the systemic impairment that occurs secondary to CKD-MBD, thus slowing the progression of renal and CVD and improving patient survival. Recent insights into fibroblast growth factor (FGF) 23 have led to marked advancement in interpreting data on CVD and CKD progression ascribing to FGF23 a pivotal role in these pathologies independent of its co-receptor klotho and well beyond mineral metabolism. This review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD.

Original languageEnglish (US)
Pages (from-to)83-95
Number of pages13
JournalContributions to Nephrology
Volume190
DOIs
StatePublished - 2017

Fingerprint

Chronic Renal Insufficiency
Minerals
Cardiovascular Diseases
Chronic Kidney Disease-Mineral and Bone Disorder
Kidney
Left Ventricular Hypertrophy
Blood Vessels
Disease Progression
fibroblast growth factor 23
Biomarkers
Pathology
Inflammation
Bone and Bones
Survival
Mortality

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Grabner, A., Mazzaferro, S., Cianciolo, G., Krick, S., Capelli, I., Rotondi, S., ... Faul, C. H. (2017). Fibroblast Growth Factor 23: Mineral Metabolism and beyond. Contributions to Nephrology, 190, 83-95. https://doi.org/10.1159/000468952

Fibroblast Growth Factor 23 : Mineral Metabolism and beyond. / Grabner, Alexander; Mazzaferro, Sandro; Cianciolo, Giuseppe; Krick, Stefanie; Capelli, Irene; Rotondi, Silverio; Ronco, Claudio; La Manna, Gaetano; Faul, Christian H.

In: Contributions to Nephrology, Vol. 190, 2017, p. 83-95.

Research output: Contribution to journalArticle

Grabner, A, Mazzaferro, S, Cianciolo, G, Krick, S, Capelli, I, Rotondi, S, Ronco, C, La Manna, G & Faul, CH 2017, 'Fibroblast Growth Factor 23: Mineral Metabolism and beyond', Contributions to Nephrology, vol. 190, pp. 83-95. https://doi.org/10.1159/000468952
Grabner A, Mazzaferro S, Cianciolo G, Krick S, Capelli I, Rotondi S et al. Fibroblast Growth Factor 23: Mineral Metabolism and beyond. Contributions to Nephrology. 2017;190:83-95. https://doi.org/10.1159/000468952
Grabner, Alexander ; Mazzaferro, Sandro ; Cianciolo, Giuseppe ; Krick, Stefanie ; Capelli, Irene ; Rotondi, Silverio ; Ronco, Claudio ; La Manna, Gaetano ; Faul, Christian H. / Fibroblast Growth Factor 23 : Mineral Metabolism and beyond. In: Contributions to Nephrology. 2017 ; Vol. 190. pp. 83-95.
@article{e8844dcba82f4340beef81896b407cff,
title = "Fibroblast Growth Factor 23: Mineral Metabolism and beyond",
abstract = "Patients affected by chronic kidney disease (CKD) exhibit a high risk of cardiovascular mortality that is poorly explained by traditional risk factors. There is a growing awareness about the role of derangement of mineral metabolism that is currently accepted as a trigger and sustainer of cardiovascular disease (CVD) in CKD patients. The synthetic definition of CKD mineral and bone disorder (CKD-MBD) split the concept that the indexes of mineral metabolism extend their effects beyond the bone until the vascular wall and metabolic milieu of CKD patients through complex pathways. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy, CVD, inflammation, and chronic renal damage may help with the diagnosis and treatment of the systemic impairment that occurs secondary to CKD-MBD, thus slowing the progression of renal and CVD and improving patient survival. Recent insights into fibroblast growth factor (FGF) 23 have led to marked advancement in interpreting data on CVD and CKD progression ascribing to FGF23 a pivotal role in these pathologies independent of its co-receptor klotho and well beyond mineral metabolism. This review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD.",
author = "Alexander Grabner and Sandro Mazzaferro and Giuseppe Cianciolo and Stefanie Krick and Irene Capelli and Silverio Rotondi and Claudio Ronco and {La Manna}, Gaetano and Faul, {Christian H}",
year = "2017",
doi = "10.1159/000468952",
language = "English (US)",
volume = "190",
pages = "83--95",
journal = "Contributions to Nephrology",
issn = "0302-5144",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Fibroblast Growth Factor 23

T2 - Mineral Metabolism and beyond

AU - Grabner, Alexander

AU - Mazzaferro, Sandro

AU - Cianciolo, Giuseppe

AU - Krick, Stefanie

AU - Capelli, Irene

AU - Rotondi, Silverio

AU - Ronco, Claudio

AU - La Manna, Gaetano

AU - Faul, Christian H

PY - 2017

Y1 - 2017

N2 - Patients affected by chronic kidney disease (CKD) exhibit a high risk of cardiovascular mortality that is poorly explained by traditional risk factors. There is a growing awareness about the role of derangement of mineral metabolism that is currently accepted as a trigger and sustainer of cardiovascular disease (CVD) in CKD patients. The synthetic definition of CKD mineral and bone disorder (CKD-MBD) split the concept that the indexes of mineral metabolism extend their effects beyond the bone until the vascular wall and metabolic milieu of CKD patients through complex pathways. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy, CVD, inflammation, and chronic renal damage may help with the diagnosis and treatment of the systemic impairment that occurs secondary to CKD-MBD, thus slowing the progression of renal and CVD and improving patient survival. Recent insights into fibroblast growth factor (FGF) 23 have led to marked advancement in interpreting data on CVD and CKD progression ascribing to FGF23 a pivotal role in these pathologies independent of its co-receptor klotho and well beyond mineral metabolism. This review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD.

AB - Patients affected by chronic kidney disease (CKD) exhibit a high risk of cardiovascular mortality that is poorly explained by traditional risk factors. There is a growing awareness about the role of derangement of mineral metabolism that is currently accepted as a trigger and sustainer of cardiovascular disease (CVD) in CKD patients. The synthetic definition of CKD mineral and bone disorder (CKD-MBD) split the concept that the indexes of mineral metabolism extend their effects beyond the bone until the vascular wall and metabolic milieu of CKD patients through complex pathways. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy, CVD, inflammation, and chronic renal damage may help with the diagnosis and treatment of the systemic impairment that occurs secondary to CKD-MBD, thus slowing the progression of renal and CVD and improving patient survival. Recent insights into fibroblast growth factor (FGF) 23 have led to marked advancement in interpreting data on CVD and CKD progression ascribing to FGF23 a pivotal role in these pathologies independent of its co-receptor klotho and well beyond mineral metabolism. This review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD.

UR - http://www.scopus.com/inward/record.url?scp=85020295627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020295627&partnerID=8YFLogxK

U2 - 10.1159/000468952

DO - 10.1159/000468952

M3 - Article

C2 - 28535521

AN - SCOPUS:85020295627

VL - 190

SP - 83

EP - 95

JO - Contributions to Nephrology

JF - Contributions to Nephrology

SN - 0302-5144

ER -